JP2014533098A5 - - Google Patents

Info

Publication number

JP2014533098A5

JP2014533098A5 JP2014536148A JP2014536148A JP2014533098A5 JP 2014533098 A5 JP2014533098 A5 JP 2014533098A5 JP 2014536148 A JP2014536148 A JP 2014536148A JP 2014536148 A JP2014536148 A JP 2014536148A JP 2014533098 A5 JP2014533098 A5 JP 2014533098A5

Authority

JP

Japan

Prior art keywords

seq

nucleic acid

acid molecule

group

type

Prior art date

2012-10-22

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Pending

Links

• Espacenet
• Global Dossier
• Discuss

• 239000002773 nucleotide Substances 0.000 claims 56
• 125000003729 nucleotide group Chemical group 0.000 claims 56
• 108020004707 nucleic acids Proteins 0.000 claims 27
• 102000039446 nucleic acids Human genes 0.000 claims 27
• 150000007523 nucleic acids Chemical class 0.000 claims 23
• 239000000523 sample Substances 0.000 claims 14
• 102000051325 Glucagon Human genes 0.000 claims 10
• 108060003199 Glucagon Proteins 0.000 claims 10
• MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims 10
• 229960004666 glucagon Drugs 0.000 claims 10
• 239000005547 deoxyribonucleotide Substances 0.000 claims 8
• 238000001514 detection method Methods 0.000 claims 7
• 108091028664 Ribonucleotide Proteins 0.000 claims 6
• 239000005557 antagonist Substances 0.000 claims 6
• 230000000694 effects Effects 0.000 claims 6
• 230000001404 mediated effect Effects 0.000 claims 6
• 239000002336 ribonucleotide Substances 0.000 claims 6
• 125000002652 ribonucleotide group Chemical group 0.000 claims 6
• 230000000295 complement effect Effects 0.000 claims 4
• 206010012601 diabetes mellitus Diseases 0.000 claims 4
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
• 238000000034 method Methods 0.000 claims 4
• 239000002202 Polyethylene glycol Substances 0.000 claims 3
• 229920001223 polyethylene glycol Polymers 0.000 claims 3
• 208000002249 Diabetes Complications Diseases 0.000 claims 2
• 206010012655 Diabetic complications Diseases 0.000 claims 2
• 206010051161 Hyperglucagonaemia Diseases 0.000 claims 2
• 241001465754 Metazoa Species 0.000 claims 2
• 201000010099 disease Diseases 0.000 claims 2
• 208000035475 disorder Diseases 0.000 claims 2
• 239000003814 drug Substances 0.000 claims 2
• 230000035880 hyperglucagonemia Effects 0.000 claims 2
• 238000004519 manufacturing process Methods 0.000 claims 2
• 230000002265 prevention Effects 0.000 claims 2
• 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims 1
• 229920001612 Hydroxyethyl starch Polymers 0.000 claims 1
• 229930182558 Sterol Natural products 0.000 claims 1
• 239000013543 active substance Substances 0.000 claims 1
• 239000000654 additive Substances 0.000 claims 1
• 230000000996 additive effect Effects 0.000 claims 1
• 239000003937 drug carrier Substances 0.000 claims 1
• WZHBYTVHUFURPY-UHFFFAOYSA-N ethyl 8'-methyl-2',5-dioxo-2-piperidin-1-ylspiro[cyclopentene-3,3'-imidazo[1,2-a]pyridine]-1-carboxylate Chemical compound N12C=CC=C(C)C2=NC(=O)C21CC(=O)C(C(=O)OCC)=C2N1CCCCC1 WZHBYTVHUFURPY-UHFFFAOYSA-N 0.000 claims 1
• 230000029142 excretion Effects 0.000 claims 1
• 150000004676 glycans Chemical class 0.000 claims 1
• 229940050526 hydroxyethylstarch Drugs 0.000 claims 1
• 230000014759 maintenance of location Effects 0.000 claims 1
• 238000012986 modification Methods 0.000 claims 1
• 230000004048 modification Effects 0.000 claims 1
• 239000008194 pharmaceutical composition Substances 0.000 claims 1
• -1 polyoxypropylene Polymers 0.000 claims 1
• 229920001451 polypropylene glycol Polymers 0.000 claims 1
• 229920001282 polysaccharide Polymers 0.000 claims 1
• 239000005017 polysaccharide Substances 0.000 claims 1
• 108090000765 processed proteins & peptides Proteins 0.000 claims 1
• 102000004169 proteins and genes Human genes 0.000 claims 1
• 108090000623 proteins and genes Proteins 0.000 claims 1
• 238000012216 screening Methods 0.000 claims 1
• 150000003432 sterols Chemical class 0.000 claims 1
• 235000003702 sterols Nutrition 0.000 claims 1